Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Karyopharm Therapeutics (KPTI) Cost of Revenue (2019 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Cost of Revenue for 5 consecutive years, with $1.3 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Cost of Revenue rose 19.27% year-over-year to $1.3 million, compared with a TTM value of $6.0 million through Dec 2024, up 31.39%, and an annual FY2025 reading of $5.9 million, down 0.97% over the prior year.
  • Cost of Revenue was $1.3 million for Q4 2024 at Karyopharm Therapeutics, up from $1.3 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $1.9 million in Q1 2024 and bottomed at $589000.0 in Q3 2021.
  • Average Cost of Revenue over 4 years is $1.2 million, with a median of $1.2 million recorded in 2023.
  • The sharpest move saw Cost of Revenue surged 151.75% in 2022, then crashed 40.26% in 2023.
  • Year by year, Cost of Revenue stood at $742000.0 in 2021, then soared by 151.75% to $1.9 million in 2022, then plummeted by 40.26% to $1.1 million in 2023, then rose by 19.27% to $1.3 million in 2024.
  • Business Quant data shows Cost of Revenue for KPTI at $1.3 million in Q4 2024, $1.3 million in Q3 2024, and $1.5 million in Q2 2024.